Live Breaking News & Updates on அமுதம் ஆரோக்கியம் பொது உறவுகள்|Page 5

Share:
SALT LAKE CITY, Dec. 28, 2020 /PRNewswire/  Elevar Therapeutics, Inc. ( Elevar ), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced that it has entered into an exclusive agreement with Inceptua Group ( Inceptua ) for the distribution and commercialization of Apealea® (paclitaxel micellar) in Europe. Apealea has been authorized by European regulatory authorities for use in the European Economic Area in combination with carboplatin for the treatment of adult patients with first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.  ....

United States , South Korea , Lindsay Rocco , Inceptua Pharma , Alex Kim , Stefan Fraenkel , Histochem Cytochem , Inceptua Group , European Commission , Drug Administration , Elevar Therapeutics Inc , Inceptua Services , Elixir Health Public Relations , American Cancer Society About Ovarian , Elevar Therapeutics , European Economic Area , Chief Executive Officer , Orphan Drug Designation , Orphan Drug , North America , Media Contact , American Cancer Society , Ovarian Cancer , Accessed November , ஒன்றுபட்டது மாநிலங்களில் , தெற்கு கொரியா ,